Case Control Study
Copyright ©The Author(s) 2019.
World J Clin Cases. Feb 26, 2019; 7(4): 431-440
Published online Feb 26, 2019. doi: 10.12998/wjcc.v7.i4.431
Table 3 Comparison between the observation group and control group at the time of admission n (%)
Control group (n = 48)Observation group (n = 48)t/χ2P-value
Baseline data
Age (yr)2.48 ± 1.712.51 ± 1.790.0840.933
Gender (male/female)32/1632/160.0001.000
Temperature (°C)37.58 ± 1.0338.26 ± 1.451.5970.114
Weight (kg)15.24 ± 2.6814.39 ± 1.471.9270.057
Primary infection site
Pulmonary infection28 (58.3)31 (64.6)0.3960.529
Digestive system infections17 (35.4)16 (33.3)0.0460.830
Blood system infection10 (20.8)7 (14.6)0.6430.423
Basic disease
Blood system diseases33 (70.2)32 (66.7)0.0480.827
Congenital heart disease11 (22.9)8 (16.7)0.5910.442
Treatment measures
Antibacterial treatments within 1 h40 (83.3)33 (68.8)2.8020.094
Duration of mechanical ventilation (h)83.41 ± 35.17144.36 ± 52.556.6780.000
Duration of vasoactive drug maintenance (h)74.02 ± 31.9078.16 ± 42.560.5390.591
Complication
ARDS13 (27.1)15 (31.3)0.2020.653
Shock21 (43.8)35 (72.9)8.4000.004
Number of organs with dysfunction1.76 ± 0.783.42 ± 1.516.7670.000
Laboratory examination
WBC (×109/L)13.96 ± 2.8512.74 ± 3.211.9690.052
PLT (×109/L)107.38 ± 33.7085.26 ± 45.352.7120.008
Hb (g/L)105.03 ± 20.25104.42 ± 22.190.1410.888
PCT (ng/mL)7.48 ± 4.5119.97 ± 6.3811.1770.000
CRP (ng/mL)115.67 ± 66.23135.14 ± 77.621.3240.189
ALB (g/L)40.11 ± 2.5733.57 ± 4.978.0980.000
sCD163 (mg/L)165.31 ± 175.26253.66 ± 216.812.1960.031
DD (μg/L)802.16 ± 269.081648.93 ± 502.5510.2820.000
Lac (mmol/L)3.22 ± 2.137.69 ± 5.245.4750.000
Cr (μmol/L)452.56 ± 348.72336.15 ± 356.801.6170.109
Children's score
PEWS5.35 ± 1.897.22 ± 1.435.4670.000